Important notice
Cancer Communications 2021年影响因子突破15分
Cancer Communications 进入2021年中科院期刊分区表医学1区和肿瘤学1区
Cancer Communications 入选中国科协发布的高质量肿瘤学科技期刊T1分级目录
Cancer Communications (CJC) 获评“2019中国最具国际影响力学术期刊”
μ-opioid receptor agonist facilitates circulating tumor cell formation in bladder cancer via the MOR/AKT/Slug pathway: a comprehensive study including randomized controlled trial
Xiaoqiang Wang, Song Zhang, Di Jin, Jiamei Luo, Yumiao Shi, Yiqi Zhang, Lingling Wu, Yanling Song, Diansan Su, Zhiying Pan, Haige Chen, Ming Cao, Chaoyong Yang, Weifeng Yu, Jie Tian
Prognostic impact of circulating tumor cells in patients with soft-tissue sarcomas: a prospective study
Julie Blanchi, Audrey Laroche-Clary, Fran?ois Le Loarer, Benjamin Bonhomme, Antoine Italiano
Impact of small molecule-mediated inhibition of ammonia detoxification on lung malignancies and liver metabolism
Georgios Makris, Semih Kayhan, Marvin Kreuzer, Véronique Rüfenacht, Erica Faccin, Jarl Underhaug, Carmen Diez-Fernandez, Philip A. Knobel, Martin Poms, Nadine Gougeard, Vicente Rubio, Aurora Martinez, Martin Pruschy, Johannes H?berle
A nanotherapeutic strategy to target drug-tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer
Tatiana Shaurova, Lingyue Yan, Yafei Su, Laurie James Rich, Vui King Vincent-Chong, Hannah Calkins, Saraswati Pokharel, Martin Petkovich, Mukund Seshadri, Yun Wu, Pamela Anne Hershberger
Combination of photodynamic therapy and stimulator of interferon genes (STING) agonist inhibits colorectal tumor growth and recurrence
Yang Hao, Sen Ma, Zili Gu, Alireza Haghparast, Timo Schomann, Zhenfeng Yu, Yuanyuan He, Xiaoxv Dong, Luis J Cruz, Peter ten Dijke
Criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in China: from the perspective of clinical reviewers
Limin Zou, Yueli Qi, Yongling Jiang, Ling Tang, Yu Du, Boyuan Zhao, Yanzhe Sun, Meiyi Xiang, Jun Ma, Zhimin Yang
Dynamic epi-transcriptomic landscape mapping with disease progression in estrogen receptor-positive breast cancer
Stephen Keelan, Mihaela Ola, Sara Charmsaz, Sinéad Cocchiglia, Daniela Ottaviani, Seán Hickey, Siobhan Purcell, Fiona Bane, Aisling Hegarty, Ben Doherty, Katherine Sheehan, Lance Hudson, Nicola Cosgrove, Benjamin Roux, Muriel Laine, Geoffrey Greene, Damir
Impact of prior chemotherapy with two different fluoropyrimidines on the efficacy of capecitabine plus irinotecan or FOLFIRI with or without bevacizumab in metastatic colorectal cancer: a post hoc analysis of the AXEPT study
Satoru Iwasa, Zi-Xian Wang, Kei Muro, Satoshi Morita, Young Suk Park, Dongsheng Zhang, Yasuhide Yamada, Junichi Sakamoto, Tae Won Kim
Aerobic glycolysis promotes tumor immune evasion and tumor cell stemness through the noncanonical function of hexokinase 2
Haiyan He, Liwei Xiao, Juhong Wang, Dong Guo, Zhimin Lu
METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression
Peng Xia, Hao Zhang, Haofeng Lu, Kequan Xu, Xiang Jiang, Yuke Jiang, Xiangdong Gongye, Zhang Chen, Jie Liu, Xi Chen, Weijie Ma, Zhonglin Zhang, Yufeng Yuan
Gastric cancer |
|
Edited by Yun Dai and Li Yan |
This thematic series discusses the molecular classifications of gastric cancer by the Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) as well as the implications in personalized therapeutic choices; discusses the evolution of gastric surgery and presents perspectives on surgical techniques in treating gastric cancer; and reviews current and emerging targeted agents as well as immunotherapies in treating gastric cancer. With these advancements in molecular characterization, surgical intervention, and targeted and immunotherapies, gastric cancer will enter a personalized medicine era in the next 5 years.
|
- - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Tumor angiogenesis |
|
Edited by Francesco Pezzella
|
Forming efficient vasculature network, also known as tumor angiogenesis, is a critical hallmark in tumor development. Explorations on its underlying molecular mechanisms have resulted in several novel anti-cancer drugs. However, the modest survival benefits from anti-angiogenic therapy have forced us to revisit our understanding on tumor angiogenesis. In this special issue, world-leading experts have contributed their critical thoughts to reveal alternative tumor angiogenesis approaches and potential treatment targets.
|
- - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Lung cancer |
|
 Edited by Lin Yan and Wei Zhang
|
Lung cancer accounts for approximately 21% of worldwide cancer deaths and a staggering 1.6 million new cases are diagnosed every year. In China, lung cancer has become a particularly challenging disease because of air pollution and smoking. This thematic series discusses the proper use of targeted agents in treating lung cancer, reviews the application of biomarkers in clinical management and drug development, and analyzes the unique challenges in developing novel drugs for lung cancer in China.
|
CC adopts ScholarOne Manuscripts
to manage its submissions from Nov.1, 2019
Submission Guidelines
Reference style for
CC is now published by Wiley
© Cancer Communications
651 Dongfeng Road East,Guangzhou 510060, P.R.China
